Abstract. We investigated effects of sasanquasaponin (SQS), a traditional Chinese herb's effective component, on ischemia and reperfusion injury in mouse hearts and the possible role of intracellular Cl -homeostasis on SQS's protective effects during ischemia and reperfusion. An in vivo experimental ischemia model was made in mice (weight 27 -45 g) using ligation of left anterior descending coronary artery, and in vitro models were made in perfused hearts by stopping flow or in isolated ventricular myocytes by hypoxia. The in vivo results showed that SQS inhibited cardiac arrhythmias during ischemia and reperfusion. Incidence of arrhythmias during ischemia and reperfusion, including ventricular premature beats and ventricular fibrillation, was significantly decreased in the SQS-pretreated group (P<0.05). Results in perfused hearts showed that SQS suppressed the arrhythmias, prevented against ischemia-induced decrease in contract force and promoted the force recovery from reperfusion. ] i during ischemia and reperfusion (P<0.05). Our results showed that SQS protected against ischemia / reperfusion-induced cardiac injury in mouse hearts and that modulation of intracellular Cl -homeostasis by SQS would play a role in its anti-arrhythmia effects during ischemia and reperfusion.
Introduction
The genetically altered mouse models provide important insights into a wide variety of processes in cardiovascular electrophysiology, pathophysiology, and development of hearts (1 -3) . Therefore, many investigators make an ischemia and reperfusion model in the mouse and use this model to estimate the cardiac physiology or electrophysiological functions in some genetically altered mice to understand the complex pathophysiology of ischemia and reperfusion injury (4 -6) . The mouse model can provide a powerful tool to further our understanding of basic mechanisms that underlie human cardiac electrophysiology or pathophysiology in some cardiac diseases (7) .
Because the cardiac diseases still seriously influence human health, the cardiac injury occurring during the ischemia and reperfusion period have been a subject of investigation for many years, and the study in development of new anti-arrhythmia drugs is still an important but imminent work. According to this strategy, our group began to search for some effective anti-arrhythmia drugs from Chinese traditional medicine and herbs. Sasanquasaponin 3) ]-b -D-glucopyrano-siduronic acid, SQS), one of the effective components of Chinese traditional herbs, was a mixture of many kinds of saponin structures origin from sasanqua Camellia oleifera ABEL (Fig. 1) . The main structure of SQS is a triterpenoid and similar to the structure of some ginseng saponins (8, 9) . On the other hand, it was known that SQS had many pharmacological effects, including antiinflammation, anti-hyperlipidemia, and anti-effusion. Our recent studies also showed that SQS effectively protected against myocardium injury in an isoproterenolinduced ischemia model in the rat in vivo or in a hypoxia and reoxygenation model in Langendorff-perfused rat hearts in vitro (10, 11) . However, although some possibilities, including inhibition of ischemia-induced Ca 2+ overload by SQS, were speculated, it is still unclear what mechanisms were involved in the effects of SQS on ischemia-induced deterioration in cardiac cells. To answer this question and to systemically investigate whether the ischemia and reperfusion model in mouse is a useful tool in research on cardiac electrophysiological characteristics or not, we utilized the ischemia and reperfusion model in whole mouse hearts in vivo or in perfused mouse hearts in vitro, and we examined the possible conservation action for SQS on ischemia and reperfusion injury in mouse hearts. Then, if SQS had any protective effects on cardiac tissues during ischemia and reperfusion in the mouse, we asked whether changes in intracellular Cl -homeostasis play any role in the protective effects of SQS or not. Accordingly, in the present study, we examined effects of SQS on intracellular Cl -homeostasis in single mouse ventricular myocytes during hypoxia and reoxygenation with fluorescence dye methods. Our study provided systemic data to show that SQS provides effective protection against ischemia and reperfusion-induced cardiovascular injury in mouse hearts and suggest that the mouse model is a useful tool for investigating cardiac ischemia and reperfusion injury.
Materials and Methods

Experiments in vivo
Ischemia and reperfusion model in mouse hearts in vivo: Adult male ICR mice (Charles River Japan, Inc., Yokohama), age 12 -18 weeks (weight 27 -45 g), were used in this study, and all animals were handled in accordance with "Rules of the Animal Experimentation Committee, Kumamoto University, School of Medicine". Animals were anesthetized with intraperitoneal injection of pentobarbital (50 -60 mg / kg); and then they were tracheotomized, intubated, and ventilated with a small animal ventilator (SAR-830/ P; CWE, Ardmore, PA, USA). The tidal volume and ventilation rate were 0.5 -0.6 ml and 100 -120 strokes per min, respectively. Thoracotomy was performed through the third intercoastal space of the left side, and the pericardium was opened as previously described (12 -14) . Then, 7-0 silk threads were passed around the left anterior descending coronary artery (LAD) using a tapered needle. Electrodes were placed to record the second limb electrocardiogram (ECG) through experiments. The artificial acute myocardial ischemia was induced by ligation of LAD. Myocardial ischemia was confirmed by regional cyanosis and S-T segment elevation in the ECG. Reperfusion was induced by releasing the ligation and confirmed by a rapid color change in the surface of the myocardium. The arrhythmias were observed and the incidence of arrhythmias during ischemia and reperfusion was analyzed.
Measurements of blood pressure (BP), dP /dT and infusion of SQS: A cervical incision was made, the trachea was intubated, and the animal was connected to a volume-cycled ventilator as described above. Then, a PE 10 flame-stretched, fluid-catheter was introduced into the left common carotid artery and attached to a transducer element (AP-621G; Nihon Kohden, Tokyo) for BP recording, and the signal was transferred by EG-600G for dP / dT recording. The second cannula using a PE 10 catheter was inserted to the left femoral vein for injection of drugs. BP, dP / dT, and heart rates (HR) were monitored continuously during the following protocols and recorded on a thermal arraycorder (WR8500-UM-101; Graphtec, Yokohama) per 5 min or saved on a magneto-optical disk and analyzed by the PowerLab system (BRC, Tokyo) in a Macintosh computer.
Experiments in vitro
Preparation of isolated mouse hearts: Isolated heart preparation was performed using a method modified for the mouse heart as described (15) . Mice (ICR, 25 -35 g) were injected intravenously with heparin (5000 
U/ kg). After 30 min, the mice were anesthetized with sodium pentobarbital (50 -60 mg / kg, i.p.), and the thorax was opened. The heart was quickly excised, placed in ice-cold saline, and immediately mounted, via the ascending aorta, onto a perfusion apparatus. The heart was perfused with a non-recirculating perfusate at a constant flow (1.6 ± 0.1 ml / min) and pressure of approximately 100 mmHg (Langendorff preparation). The perfusate was a modified Tyrode solution containing: 127 mM NaCl, 4.7 mM KCl, 0.25 mM MgCl 2 , 1.2 mM KH 2 PO 4 , 5.5 mM glucose, and 2.5 mM CaCl 2 . The perfusate was equilibrated with 5% CO 2 / 95% O 2 at 37°C, and pH was adjusted with 20 or 25 mM NaHCO 3 to 7.4. The perfusate in the reservoir was continuously pumped through a 3-mm filter to prevent particulate matter from entering the coronary circulation.
Action potential recording in isolated ventricular papillary muscles: Mice were stunned, and their hearts were quickly removed, placed in a cold Tyrode solution, and superfused continuously at approximately 5 ml / min with the oxygenized normal Tyrode solution (composition was as described above except CaCl 2 was changed to 1.8 mM). The temperature of the bath solution was monitored using a thermocouple-type thermoprobe (PTC-201; Unique Medical, Tokyo) placed in the bath chamber set at 36 ± 0.5°C. The preparations were equilibrated without stimulation for 1 h before the start of the experiment and were then stimulated electrically with a pair of bipolar electrodes that delivered 0.1-ms pulses, with intensity twice the diastolic threshold unless otherwise specified. Transmembrane potentials were recorded with conventional glass microelectrodes filled with 3 M KCl and with a resistance ranging from 10 to 20 MW. The microelectrode recording were displayed and analyzed with a PowerLab system.
Preparation of isolated single mouse cardiomyocytes: To obtain single mouse ventricular myocytes, mouse hearts were isolated from adult male ICR mice anesthetized with diethyl ether and Langendorff-perfused for 10 min with oxygenized normal Tyrode solution at 37°C. A brief perfusion with a Ca
2+
-free Tyrode solution containing 0.1% bovine serum albumin (Fraction V; Sigma, St. Louis, MO, USA) followed, after which the hearts were treated with 0.06% collagenase (YK-102; Yakult, Tokyo) in the same solution as described (16) . After 30-min collagenase treatment, the ventricles were minced and incubated for 20 min with stirring in albumin-free Tyrode solution containing 0.2 mM Ca 2+ and 0.001% trypsin (Type 3, Sigma). The cells obtained by pipetting were filtered through 120-mm nylon mesh, centrifuged (85 -100´g for 3 min), and resuspended in the normal Tyrode solution. The Ca
-tolerant rod-shaped cells were used for experiments. All experiments were finished within 24 h.
Hypoxia and reoxygenation model in single myocytes: Myocytes were perfused initially with a normal Tyrode solution equilibrated with a gas mixture of 95% O 2 / 5% CO 2 and pH was adjusted to 7.4 at 37°C. To simulate hypoxia and reoxygenation, we switched to modified Tyrode solution pH 6.8 at 37°C without glucose to prevent glycolysis and aerated the cells with a gas mixture of 95% N 2 / 5% CO 2 before treating them with normal Tyrode solution. Cl -or HCO 3 --free solution was prepared by equimolar substitution with gluconate or HEPES, respectively. The perfusion rate was fixed at 1.0 ml / min with a peristaltic pump throughout the experiment, and it took approximately 30 s to change the perfusion media in the chamber.
Measurement of [Cl -
] i with MQAE fluorescence dyes:
] i measurements, isolated ventricular myocytes were incubated with 5 mM N-(6-methoyquinolyl)acetoxyacetyl-ester (MQAE; Dojindo Laboratories, Kumamoto) for 60 min at 37°C. Then the cells were washed with the Tyrode solution, and the cells were placed on a poly-L-lysine-coated mounted coverslip dish (35-mm diameter, MatTek Corp., Ashland, MA, USA) and incubated for 30 min. Then, microfluorometric measurements were made with an image processor system (ACOUScosmos; Hamamatsu Photonics Corp., Hamamatsu) as described (17) . The fluorescence intensity of MQAE was collected and stored on a magnetooptical disk every 4 s until analysis.
Calibration of intracellular MQAE: The myocytes were resuspended in an experimental Cl --free solution (NaCl was substituted by equimolar amounts of Dglucuronic acid; MgCl 2 , by MgSO 4 ; KCl, by potassium gluconate), centrifuged once, and resuspended in a cuvette with 350 m l of Cl --free medium plus 10 mM glucose and 0.1% BSA. The fluorescence intensity was monitored using an ACOUScosmos imaging system (excitation 350 nm, emission 460 nm) at room temperature (24°C).
Calibration of intracellular MQAE intensity was performed by determining the correlation between fluorescence intensity and Cl -concentration by a procedure modified from those described by Krapf et al. (18) . The maximal fluorescence in the absence of Cl -was obtained by depleting intracellular Cl -by adding the ionophores nigericin (7 m M) and tributylin acetate (10 m M) to the isolated mouse ventricular myocytes in the Cl -ion has a much high affinity for the indicator than Cl -ion and therefore quenches most of the MQAE fluorescence at the given Cl -concentration minus F KSCN . The calibration cure of intracellular MQAE was obtained from the data. The Cl --free solution was made by replacement of Cl -with equimolar gluconate as described previously (19) .
Reagents and statistical analyses
All salts for preparing solutions and poly-L-lysine and other pharmacological agents were purchased from Sigma. Sodium gluconate, potassium gluconate, and calcium gluconate monohydrate were purchased from Wako (Osaka). Sasanquasaponin (C 58 H 92 O 26 , FW is 1204.0352) was extracted and isolated from Camellia oleifera ABEL and purified by the previously described method (20) . Data were analyzed by basic statistical methods, including analysis of the two-tailed Student's t-test (unpaired) and ANOVA or Chi-square test and expressed as the arithmetic means ± S.E.M. A P<0.05 value was considered to be statistically significant.
Results
SQS slightly inhibited HR and decreased BP in nonischemia mice
We examined effects of SQS on BP and HR in nonischemia mice. SQS at a concentration of 0.1 mg / kg slightly decreased HR from 347 ± 24 beats/ min of the control to 307 ± 40 beats / min at 10 min after application of drugs (n = 9, P<0.05). After intravenous injection of SQS at 0.1 mg / kg, BP was immediately decreased from 91 ± 7 mmHg in the control to 70 ± 12 mmHg, and this decrease was continued to 10 min after administration of the drug (Fig. 2: A and B, n = 9, P<0.05). However, even though it still inhibited HR at high concentrations (0.2, 0.4 mg / kg), SQS increased BP and got a peak level of BP at 98 ± 14 or 102 ± 10 mmHg, respectively ( Fig. 2 : B and C, P<0.05).
SQS inhibited incidence of arrhythmias during ischemia and reperfusion in vivo
Then we observed the effects of SQS on ischemia and reperfusion injury in vivo. The mouse received 30-min ischemia following 30-min reperfusion; then BP and HR was recorded and the incidence of arrhythmia during ischemia and reperfusion were observed. The arrhythmia type observed during the ischemia and reperfusion period included ventricular premature beats (VPB); escape beats (EB); bradycardia (BR), bradycardia and tachycardia (B and T), bigeminy (BG); salvos (SA); ectopic beats (EC); ventricular tachycardia (VT); ventricular fibrillation (VF); AV dissociation (AVD) (see Fig. 3A ). The arrhythmia type in mouse in vivo was similar to that occurring in the rat (13, 21, 22) , rabbit (23), or dog (24, 25) . However, the incidence of arrhythmias was different from other animal types (26) . In the present study, we showed that during the ischemia period, the incidence of VT and VF was relatively lower (VT, 4 / 13, 30.7%; VF, 2 / 13, 15.4%) and the incidences of BR and EB or AVD were relatively higher. Similar results were also observed in the reperfusion period (Fig. 3B) .
When mice were injected with intravenous administration of SQS 10 min before ligation of LAD, the incidences of arrhythmias during both ischemia and reperfusion periods in mouse hearts were decreased (Fig. 3B , Chi-square test, P<0.05). However, there was no significantly change in systolic BP in the SQS-treated group compared with that in the non-SQS-treated group (LAD ligation induced decrease in systolic BP about 20 mmHg). Furthermore, we investigated the direct effects of SQS on arrhythmia that occurred during ischemia and reperfusion in some cases. In these experiments, the ischemia and reperfusion model was made by the same protocol as above (30-min ischemia followed by 30-min reperfusion), and the ECG, BP, and dP / dT were persistently monitored. However, SQS was not pretreated before ischemia but was immediately administrated with intravenous injection once the arrhythmia appeared. Figure 4 shows a typical recording in which SQS effectively inhibited the SA type arrhythmias during reperfusion. Similar results were obtained in another 4 animals and indicated that SQS had acute treatment effects on arrhythmias, including SA-and tachy-arrhythmias, during ischemia or reperfusion (data not shown).
SQS prevented the ischemia-induced decrease in contraction force and promoted recovery from reperfusion in Langendroff-perfused hearts
We examined possible protective effects of SQS on change of contraction force in Langendorff-perfused mouse hearts during ischemia and reperfusion. The ischemia and reperfusion model was made in Langendorff-perfused mouse hearts, and the contraction force of hearts was monitored using a PowerLab system. The contraction force of hearts gradually decreased during ischemic period and then ceased at approximately 11 min after ischemia (11.6 ± 2.5 min). When the hearts begin to reperfusion with Tyrode solution, the contraction force gradually recovered to the control level. After treated with SQS 0.1 m M, the time to cessation of contraction force during ischemia was prolonged com-pared with that in the non-SQS group (P<0.05). The recovery of contraction force during the reperfusion period in the SQS-treated group was also significantly faster than that in the no-SQS group (P<0.05). Furthermore, the elevation in resting tension of muscles induced by ischemia was suppressed in the SQS-treated group (Fig. 5) .
Similarly, when the Cl -in perfused solution was replaced with iso-molar gluconate, or when hearts were perfused with SITS (4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid) at a concentration of 0.1 mM, change of contraction force during ischemia and reperfusion was the same as those obtained from SQS-treated hearts.
SQS inhibited cardiac arrhythmias during ischemia and reperfusion in vitro
We then analyzed whether SQS has any effects on incidence of ischemia and reperfusion induced arrhythmias in Langendorff-perfused mouse hearts. As shown in Table 1 , we calculated the related incidence of arrhythmias occurring in the SQS-or SITS-treated group during ischemia and reperfusion. Results showed that both SQS and SITS (a Cl --transport blocker) significantly decreased the incidence of arrhythmias that occurred in both the ischemia and reperfusion periods (compared with non-drug group, Chi-square test, P<0.05). ] i using MQAE fluorescence methods in isolated mouse cardiac myocytes (Fig. 6) . Single mouse ventricular myocytes were isolated enzymatically from mouse ventricle and then centrifuged and resuspended in a low Ca 2+ Tyrode solution followed by a normal Ca 2+ solution. In non-ischemic cardiac myocytes, the value of [Cl -] i in mouse cardiac myocytes was in the range of 25 mM -35 mM. This value was similar to previous reporters in human Jurkat T lymphocytes (17) , but slightly higher than that reported in cardiac muscles in the guinea pig (19) . However, SQS slightly decreased the [Cl -] i in the non-ischemic condition. In the non-ischemia group, the [Cl -] i was 28.6 ± 8.5 mM in the control and 18.4 ± 8.5 mM in the SQS-treated group (P<0.05). The effects of SQS were similar to the effects of SITS, a stilbene derivative, which was reported in our previous study (19) . When the cells suffered from hypoxia and reoxygenation, the Cl -was Fig. 3 . SQS protected against cardiac arrhythmias during ischemia and reperfusion. A: Type of arrhythmias that occurred during ischemia and reperfusion in mouse in vivo. VPB, ventricular premature beats; EB, escape beats; BR, bradycardia; B and T, bradycardia and tachycardia; BG, bigeminy; SA, salvos; EC, ectopic beats; VT, ventricular tachycardia; VF, ventricular fibrillation; AVD, AV dissociation. B: SQS protected against cardiac arrhythmias during ischemia and reperfusion. The incidence of arrhythmias that occurred during ischemia and reperfusion is shown in this figure. The arrhythmia occurrence during ischemia (a); the incidence of arrhythmias that occurred during the reperfusion period (b). Data showed that SQS significantly inhibited the arrhythmia during both ischemia and reperfusion periods. Open bars, control; closed bars, SQS-treated groups. *, Compared with control (Chi-square test), P<0.05. ] i during ischemia and reperfusion is similar to that by SITS (Fig. 7) .
SQS shortened the action potential duration and induced hyperpolarization in isolated ventricular papillary muscle
Because SQS decreased the BP in mice in vivo (Fig. 2) and previous reports showed that effects of SQS on isoprenaline-induced ST-elevation in rats can be suppressed by glibenclamide known as a K ATP channel blocker (10), we investigated whether SQS has any effect acting as an ATP-dependent K + channel opener on mouse ventricular muscles and measured the action potential in isolated ventricular papillary muscles using glass microelectrode techniques. As shown in Fig. 8 , SQS at a concentration of 0.1 mM shortened the action potential duration and hyperpolarized the cells. This effect of SQS can be blocked by glibenclamide at a concentration of 1 m M.
Discussion
Our results showed that SQS protected against ischemia-or hypoxia-induced deterioration in mouse hearts in vivo and in vitro. Because SQS also suppressed ischemia-induced elevation of [Cl - ] i in isolated single mouse cardiomyocytes, we suggest that SQS would play an important role in its anti-arrhythmia effects during ischemia and reperfusion in mouse cardiac cells by modulation of intracellular Cl -homeostasis. On the other hand, the ischemia and reperfusion model in the mouse in the present study reproduced the cardiac ischemia and reperfusion injury, including decrease in BP and contractile force, increase in incidence of arrhythmias, and elevation of [Cl -] i . It was similar to previous reports in the rat (27, 28) , dog (29, 30) or guinea pig (19) . Furthermore, the effect of SQS on arrhythmias in the present study was similar to that reported in the rat (10) , and the effect of SITS on ischemia-induced increase in [Cl -] i was similar to that in guinea pig ventricular muscle (19) . Therefore, it is apparent that the ischemia and reperfusion model in mouse is credible and useful.
The mechanism through which SQS protected against ischemia-and reperfusion-induced injuries in mouse hearts is complicated and still unclear. However, besides SQS's suppression on Ca 2+ overload as previously described (10), one possibility is that SQS acts as a K ATP channel opener to induce a pharmacological preconditioning like it did in the rat model described (11) or like nicorandil did in the rabbit (31) . Indeed, in the present study, we found that intravenous bolus injection of SQS at a dose of 0.1 mg/ kg transiently decreased BP, including systolic pressure and diastolic pressure. SQS at the same concentration also induced shortening of action potential duration and hyperpolarization of Fig. 4 . Representative example of a recording for the protective effects of SQS against ischemia /reperfusion induced cardiac arrhythmias in mouse hearts. The heart was subjected to 30 min ischemia followed by 30 min reperfusion; and the ECG, dP /dT, and BP were recorded. A: Representative charts of ECG, dP /dT, and BP recordings before application of SQS. Data showed that SA arrhythmias appeared at 4 min after beginning reperfusion. B: Application of SQS (0.1 mg/kg, injected with intravenous administration as indicated by an arrow) inhibited the arrhythmia. C: Data obtained at 1 min after SQS, which indicated that arrhythmia disappeared. Isolated mouse hearts (n = 12 per group) were subjected to a 10-min period of equilibration, 30 min of ischemia, and 30 min of reperfusion, and arrhythmias were observed. VPB, ventricular premature beats; BG, bigeminy; SA, salvos; VT, ventricular tachycardia; VF, ventricular fibrillation. *P<0.05 compared with controls (Chi-square test). Numerals in parentheses indicate numbers on hearts in which arrhythmias were occurred.
cells in isolated mouse ventricular muscles that can be blocked by glibenclamide, a K ATP -channel antagonist (Fig. 8 ). Thus, it is possible that SQS at a low concentration may act as an opener of ATP-dependent K + channels and resulted in a decrease of BP in vivo and APD shortening or hyperpolarization in vitro. Therefore, the protective effects of pretreatment with SQS at this concentration before starting ischemia in the mouse model in vivo and in vitro would result from SQSinduced effective preconditioning. However, the present study also showed that not only pretreatment of SQS but also immediate intravenous application of the drug inhibited the arrhythmias during ischemia and reperfusion. The data in Fig. 4 (35) . Using pH-selective microelectrodes to measure intracellular pH (pH i ) in ischemic guinea pig ventricular muscles, we also showed that the application of stilbene derivatives suppressed the rapid onset of ischemia-induced intracellular acidosis and delayed the onset of ischemia-induced deterioration of action potentials in cardiac muscles (34) . Under a Cl --free condition, the time to cessation of action potentials caused by ischemia was significantly delayed, and the development of intracellular acidosis during ischemia was attenuated. These results indicate that activation of the Cl --HCO 3 -exchange system may result in countertransport of intracellular HCO 3 -and extracellular Cl -and, therefore, is partly involved in the development of intracellular acidosis during the early phase of cardiac ischemia. Therefore, the data in the present study may provide new evidence to support a hypothesis that the inhibition of development of intracellular acidosis by decrease in activity of Cl --HCO 3 -exchanger is favorable for recovery of contractile function during ischemia and reperfusion. Furthermore, because SQS can attenuate the ischemia-induced Cl --increase by activation of K ATP channels, it is possible that this suppression effect of SQS may influence the Cl --Ca 2+ interaction by inhibition of the Cl -increase-induced Ca 2+ release from intracellular stores (36 -38) and by suppression of the ischemia-induced membrane depolarization. Then, as a result, the incidence of arrhythmias may be suppressed.
By way of summary, our findings suggest that SQS had some protective effects on ischemia-or hypoxiainduced deterioration both in vitro and in vivo. The facts that anti-arrhythmia effects of SQS in the mouse in the present study were similar to that in rats indicated that the ischemia and reperfusion model in the mouse is a useful tool to research cardiovascular diseases.
Modulation of intracellular Cl
-homeostasis by SQS would partially play a role in its anti-arrhythmia effects during ischemia and reperfusion in mouse cardiac cells. However, it is still unclear how SQS-induced-K ATP channel activation results in attenuation of intracellular Cl -accumulation during ischemia and reperfusion, and further investigations need to be undertaken. 
